Syndesi Therapeutics

Syndesi Therapeutics

Syndesi Therapeutics

Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain).
Type
B2c
Founded
2018
Raised
$21M
Follow us
Alexa global traffic share
Latest funding
Team Size
2
Employees
€17,000,000 Venture capital (Series A)
FierceBiotech

UCB spins out neuro startup with €17M from Novo, Johnson & Johnson